tert-butyl (S)-((tert-butoxycarbonyl)oxy)(6-(1,3-dibenzyl-2,5-dioxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4]diazepin-4-yl)hex-4-enoyl)carbamate | 951326-82-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (S)-((tert-butoxycarbonyl)oxy)(6-(1,3-dibenzyl-2,5-dioxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4]diazepin-4-yl)hex-4-enoyl)carbamate
• CAS: 951326-82-2
• 化学式: C₃₉H₄₅N₃O₈
• 分子量: 683.802
• InChiKey: PRCFTBNPWFALST-YTTGMZPUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.25
• 重原子数：
  50.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  122.76
• 氢给体数：
  0.0
• 氢受体数：
  8.0

反应信息

• 作为反应物：
  描述：

  tert-butyl (S)-((tert-butoxycarbonyl)oxy)(6-(1,3-dibenzyl-2,5-dioxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4]diazepin-4-yl)hex-4-enoyl)carbamate 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 以100%的产率得到
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors

  摘要：

  New histone deacetylase inhibitors have been synthesized and evaluated for their activity against non-small lung cancer cell line H661. These compounds have been designed with diversely substituted 1,4-benzodiazepine-2,5-dione moieties as cyclic peptide mimic cap structures, and a hydroxamate side chain. Biological evaluations demonstrated that benzodiazepine-based HDACi bearing an aromatic substituent at the N1 position exhibited promising anti proliferative and HDAC-inhibitory activities. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.067
• 作为产物：
  描述：

  [tert-butoxycarbonyl(pent-4-enoyl)amino] tert-butyl carbonate 、 (S)-4-allyl-1,3-dibenzyl-3,4-dihydro-1H-benzo[e][1,4]diazepine-2,5-dione 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 作用下， 反应 48.0h， 以58%的产率得到tert-butyl (S)-((tert-butoxycarbonyl)oxy)(6-(1,3-dibenzyl-2,5-dioxo-1,2,3,5-tetrahydro-4H-benzo[e][1,4]diazepin-4-yl)hex-4-enoyl)carbamate
  参考文献：
  名称：

  Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors

  摘要：

  New histone deacetylase inhibitors have been synthesized and evaluated for their activity against non-small lung cancer cell line H661. These compounds have been designed with diversely substituted 1,4-benzodiazepine-2,5-dione moieties as cyclic peptide mimic cap structures, and a hydroxamate side chain. Biological evaluations demonstrated that benzodiazepine-based HDACi bearing an aromatic substituent at the N1 position exhibited promising anti proliferative and HDAC-inhibitory activities. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.06.067